JP2019516665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516665A5 JP2019516665A5 JP2018546587A JP2018546587A JP2019516665A5 JP 2019516665 A5 JP2019516665 A5 JP 2019516665A5 JP 2018546587 A JP2018546587 A JP 2018546587A JP 2018546587 A JP2018546587 A JP 2018546587A JP 2019516665 A5 JP2019516665 A5 JP 2019516665A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- terminal
- mhc
- multimeric
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 128
- 229920001184 polypeptide Polymers 0.000 claims 117
- 102000004196 processed proteins & peptides Human genes 0.000 claims 117
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 25
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 25
- 230000002519 immonomodulatory effect Effects 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 16
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 16
- 210000004899 c-terminal region Anatomy 0.000 claims 16
- 238000000034 method Methods 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 5
- 102000043131 MHC class II family Human genes 0.000 claims 4
- 108091054438 MHC class II family Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102000043129 MHC class I family Human genes 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302654P | 2016-03-02 | 2016-03-02 | |
| US62/302,654 | 2016-03-02 | ||
| PCT/US2017/020276 WO2017151818A2 (en) | 2016-03-02 | 2017-03-01 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516665A JP2019516665A (ja) | 2019-06-20 |
| JP2019516665A5 true JP2019516665A5 (enExample) | 2020-04-09 |
Family
ID=59743228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546587A Pending JP2019516665A (ja) | 2016-03-02 | 2017-03-01 | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190062400A1 (enExample) |
| EP (1) | EP3423108A4 (enExample) |
| JP (1) | JP2019516665A (enExample) |
| KR (1) | KR20180132663A (enExample) |
| CN (1) | CN109311945A (enExample) |
| AU (1) | AU2017226269B2 (enExample) |
| CA (1) | CA3014458A1 (enExample) |
| IL (1) | IL261401A (enExample) |
| WO (1) | WO2017151818A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102208505B1 (ko) | 2012-12-11 | 2021-01-27 | 앨버트 아인슈타인 컬리지 오브 메디신 | 고처리량 수용체:리간드 확인을 위한 방법 |
| PT3283508T (pt) | 2015-04-17 | 2021-06-21 | Alpine Immune Sciences Inc | Proteínas imuno modulatórias com afinidades afináveis |
| KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
| MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
| CA3019005A1 (en) * | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US11339201B2 (en) | 2016-05-18 | 2022-05-24 | Albert Einstein College Of Medicine | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| MX2019007611A (es) | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| AU2018234628B2 (en) * | 2017-03-15 | 2023-07-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| MX2019012849A (es) | 2017-04-28 | 2019-11-28 | Five Prime Therapeutics Inc | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. |
| CA3071881A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | Antigen-presenting polypeptides and methods of use thereof |
| TW201920249A (zh) * | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP3897690A4 (en) * | 2018-12-19 | 2022-09-28 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2020181272A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| AU2020282736B2 (en) * | 2019-05-29 | 2025-10-30 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| EP4030897A4 (en) * | 2019-09-20 | 2023-10-18 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| JP7756638B2 (ja) | 2019-10-23 | 2025-10-20 | キュー バイオファーマ，インコーポレーテッド | ＴＧＦ－βポリペプチド |
| WO2021178975A1 (en) * | 2020-03-06 | 2021-09-10 | Albert Einstein College Of Medicine | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity |
| CA3174908A1 (en) * | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
| MX2022013208A (es) | 2020-05-12 | 2022-11-14 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
| WO2021242935A1 (en) * | 2020-05-26 | 2021-12-02 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| WO2021242937A2 (en) * | 2020-05-26 | 2021-12-02 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| CN116437952A (zh) * | 2020-07-14 | 2023-07-14 | 库尔生物制药有限公司 | 具有缀合位点的t细胞调节多肽及其使用方法 |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| CA3216273A1 (en) * | 2021-04-21 | 2022-10-27 | Ronald D. SEIDEL III | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof |
| US20240270815A1 (en) * | 2021-05-26 | 2024-08-15 | Cue Biopharma, Inc. | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9909472A (pt) * | 1998-04-07 | 2001-09-11 | Corixa Corp | Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica |
| KR20140058532A (ko) * | 2011-06-30 | 2014-05-14 | 겐자임 코포레이션 | Ｔ-세포 활성화 억제제 |
| CN102898504B (zh) * | 2012-10-23 | 2014-08-06 | 中国农业大学 | 抗氧化活性合成肽及其用途 |
| JP6652932B2 (ja) * | 2014-06-18 | 2020-02-26 | アルバート アインシュタイン カレッジ オブ メディシン | ｓｙｎＴａｃポリペプチド及びその使用 |
-
2017
- 2017-03-01 AU AU2017226269A patent/AU2017226269B2/en not_active Expired - Fee Related
- 2017-03-01 JP JP2018546587A patent/JP2019516665A/ja active Pending
- 2017-03-01 CN CN201780027232.8A patent/CN109311945A/zh active Pending
- 2017-03-01 EP EP17760749.6A patent/EP3423108A4/en not_active Withdrawn
- 2017-03-01 CA CA3014458A patent/CA3014458A1/en not_active Abandoned
- 2017-03-01 WO PCT/US2017/020276 patent/WO2017151818A2/en not_active Ceased
- 2017-03-01 KR KR1020187028428A patent/KR20180132663A/ko not_active Ceased
- 2017-03-01 US US16/077,420 patent/US20190062400A1/en not_active Abandoned
-
2018
- 2018-08-27 IL IL261401A patent/IL261401A/en unknown
-
2022
- 2022-08-12 US US17/887,199 patent/US20230227530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516665A5 (enExample) | ||
| JP2019512222A5 (enExample) | ||
| JP2019522465A5 (enExample) | ||
| JP2019522466A5 (enExample) | ||
| JP2020511949A5 (enExample) | ||
| JP2021500855A5 (enExample) | ||
| IL308851B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| JP2017509335A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| JP2017512063A5 (enExample) | ||
| IL272085B2 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JP2023076828A5 (enExample) | ||
| JP2020529841A5 (enExample) | ||
| JP2018512856A5 (enExample) | ||
| JP2016000731A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| JP2020500015A5 (enExample) | ||
| JP2015511637A5 (enExample) | ||
| JP2017527272A5 (enExample) | ||
| JP2018526970A5 (enExample) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2017519491A5 (enExample) | ||
| MY198621A (en) | T cell receptors | |
| JP2017535284A5 (enExample) | ||
| JP2015535816A5 (enExample) |